These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35995996)

  • 1. BMP4 and Gremlin 1 regulate hepatic cell senescence during clinical progression of NAFLD/NASH.
    Baboota RK; Rawshani A; Bonnet L; Li X; Yang H; Mardinoglu A; Tchkonia T; Kirkland JL; Hoffmann A; Dietrich A; Boucher J; Blüher M; Smith U
    Nat Metab; 2022 Aug; 4(8):1007-1021. PubMed ID: 35995996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Novel Adipokine Gremlin 1 Antagonizes Insulin Action and Is Increased in Type 2 Diabetes and NAFLD/NASH.
    Hedjazifar S; Khatib Shahidi R; Hammarstedt A; Bonnet L; Church C; Boucher J; Blüher M; Smith U
    Diabetes; 2020 Mar; 69(3):331-341. PubMed ID: 31882566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone morphogenetic protein 4 (BMP4) alleviates hepatic steatosis by increasing hepatic lipid turnover and inhibiting the mTORC1 signaling axis in hepatocytes.
    Peng Q; Chen B; Wang H; Zhu Y; Wu J; Luo Y; Zuo G; Luo J; Zhou L; Shi Q; Weng Y; Huang A; He TC; Fan J
    Aging (Albany NY); 2019 Dec; 11(23):11520-11540. PubMed ID: 31831718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Potential Role of Cellular Senescence in Non-Alcoholic Fatty Liver Disease.
    Engelmann C; Tacke F
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Connection between MicroRNAs from Visceral Adipose Tissue and Non-Alcoholic Fatty Liver Disease.
    Zubáňová V; Červinková Z; Kučera O; Palička V
    Acta Medica (Hradec Kralove); 2021; 64(1):1-7. PubMed ID: 33855952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes.
    Chen L; Wu N; Kennedy L; Francis H; Ceci L; Zhou T; Samala N; Kyritsi K; Wu C; Sybenga A; Ekser B; Dar W; Atkins C; Meadows V; Glaser S; Alpini G
    Hepatology; 2021 Oct; 74(4):1845-1863. PubMed ID: 33928675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid accumulation-induced hepatocyte senescence regulates the activation of hepatic stellate cells through the Nrf2-antioxidant response element pathway.
    Yu H; Jiang X; Dong F; Zhang F; Ji X; Xue M; Yang F; Chen J; Hu X; Bao Z
    Exp Cell Res; 2021 Aug; 405(2):112689. PubMed ID: 34107274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease.
    Jiao J; Sanchez JI; Saldarriaga OA; Solis LM; Tweardy DJ; Maru DM; Stevenson HL; Beretta L
    JHEP Rep; 2023 Feb; 5(2):100628. PubMed ID: 36687470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secretome of senescent hepatic stellate cells favors malignant transformation from nonalcoholic steatohepatitis-fibrotic progression to hepatocellular carcinoma.
    Zhou Y; Zhang L; Ma Y; Xie L; Yang YY; Jin C; Chen H; Zhou Y; Song GQ; Ding J; Wu J
    Theranostics; 2023; 13(13):4430-4448. PubMed ID: 37649614
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting senescent hepatocytes using the thrombomodulin-PAR1 inhibitor vorapaxar ameliorates NAFLD progression.
    Maeso-Díaz R; Du K; Pan C; Guy CD; Oh SH; Chen T; Wang L; Ko DC; Tang L; Dutta RK; Jun JH; Suzuki A; Abdelmalek MF; Wang XF; Diehl AM
    Hepatology; 2023 Oct; 78(4):1209-1222. PubMed ID: 37036206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracellular vesicles derived from fat-laden hepatocytes undergoing chemical hypoxia promote a pro-fibrotic phenotype in hepatic stellate cells.
    Hernández A; Reyes D; Geng Y; Arab JP; Cabrera D; Sepulveda R; Solis N; Buist-Homan M; Arrese M; Moshage H
    Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165857. PubMed ID: 32512191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.
    Majdi A; Aoudjehane L; Ratziu V; Islam T; Afonso MB; Conti F; Mestiri T; Lagouge M; Foufelle F; Ballenghien F; Ledent T; Moldes M; Cadoret A; Fouassier L; Delaunay JL; Aït-Slimane T; Courtois G; Fève B; Scatton O; Prip-Buus C; Rodrigues CMP; Housset C; Gautheron J
    J Hepatol; 2020 Apr; 72(4):627-635. PubMed ID: 31760070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular senescence in hepatocytes contributes to metabolic disturbances in NASH.
    Bonnet L; Alexandersson I; Baboota RK; Kroon T; Oscarsson J; Smith U; Boucher J
    Front Endocrinol (Lausanne); 2022; 13():957616. PubMed ID: 36072934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like Growth Factor Binding Proteins and Cellular Senescence Are Involved in the Progression of Non-Alcoholic Fatty Liver Disease and Fibrosis in a Mouse Model.
    Guzmán C; Bautista-Ubaldo MG; Campos-Espinosa A; Romero-Bello II; Santana-Vargas ÁD; Gutierrez-Reyes G
    Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541155
    [No Abstract]   [Full Text] [Related]  

  • 16. Transcriptomic differences in intra-abdominal adipose tissue in extremely obese adolescents with different stages of NAFLD.
    Sheldon RD; Kanosky KM; Wells KD; Miles L; Perfield JW; Xanthakos S; Inge TH; Rector RS
    Physiol Genomics; 2016 Dec; 48(12):897-911. PubMed ID: 27764764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis.
    Pohl R; Haberl EM; Rein-Fischboeck L; Zimny S; Neumann M; Aslanidis C; Schacherer D; Krautbauer S; Eisinger K; Weiss TS; Buechler C
    Eur J Clin Invest; 2017 Jan; 47(1):7-18. PubMed ID: 27797398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic Treatment of Non-Alcoholic Fatty Liver Disease.
    Kimura T; Singh S; Tanaka N; Umemura T
    Front Endocrinol (Lausanne); 2021; 12():773432. PubMed ID: 34938271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity.
    Larsen FT; Hansen D; Terkelsen MK; Bendixen SM; Avolio F; Wernberg CW; Lauridsen MM; Grønkjaer LL; Jacobsen BG; Klinggaard EG; Mandrup S; Di Caterino T; Siersbæk MS; Indira Chandran V; Graversen JH; Krag A; Grøntved L; Ravnskjaer K
    JHEP Rep; 2023 Feb; 5(2):100615. PubMed ID: 36687468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic targeting of adipose tissue macrophages ameliorates liver fibrosis in non-alcoholic fatty liver disease.
    Martínez-Sánchez C; Bassegoda O; Deng H; Almodóvar X; Ibarzabal A; de Hollanda A; Martínez García de la Torre RA; Blaya D; Ariño S; Jiménez-Esquivel N; Aguilar-Bravo B; Vallverdú J; Montironi C; Osorio-Conles O; Fundora Y; Sánchez Moreno FJ; Gómez-Valadés AG; Aguilar-Corominas L; Soria A; Pose E; Juanola A; Cervera M; Perez M; Hernández-Gea V; Affò S; Swanson KS; Ferrer-Fàbrega J; Balibrea JM; Sancho-Bru P; Vidal J; Ginès P; Smith AM; Graupera I; Coll M
    JHEP Rep; 2023 Oct; 5(10):100830. PubMed ID: 37701336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.